This work shows that combining metformin, a drug that inhibits complex I and reduces the NAD+/NADH ratio, with FK866, a drug that inhibits the NAD salvage enzyme NAMPT, triggers a better anticancer response than that obtained with either drug alone in several pancreatic cancer cell lines. The gene discussed is NAMPT; the disease is pancreatic neoplasm.